Skip to main content

Table 2 Evolution in overall cognitive outcomes, executive function and attention according to plasma MCP-1 status

From: Plasma MCP-1 and changes on cognitive function in community-dwelling older adults

 

Low-plasma MCP-1a

High-plasma MCP-1

Between-group differenceb

P value

Within-group evolution

Estimated mean (95% CI)c

Within-group evolution

Estimated mean (95% CI)

Estimated difference (95%CI)

Cognitive Composite Scored,n= 1079

 12 months

−0.06 (−0.15, 0.03)

−0.13 (−0.19, −0.08)

−0.08 (−0.17, 0.02)

0.114

 24 months

−0.05 (−0.15, 0.04)

−0.18 (−0.18, −0.06)

−0.07 (−0.17, 0.03)

0.196

 36 months

−0.14 (−0.24, −0.04)

−0.24 (−0.31, −0.17)

−0.10 (−0.21, 0.02)

0.091

 48 months

0.18 (0.27,0.08)

0.31 (0.39,0.24)

0.14 (0.26,0.02)

0.023

MMSE,n= 1080

 12 months

−0.04 (−0.30, −0.22)

−0.15 (−0.37, 0.07)

−0.11 (−0.38, 0.16)

0.418

 24 months

−0.03 (−0.29, 0.23)

−0.16 (−0.39, 0.08)

−0.12 (−0.41, 0.16)

0.386

 36 months

−0.21 (−0.48, 0.06)

−0.18 (−0.44, 0.08)

0.03 (−0.29, 0.34)

0.853

 48 months

−0.15 (−0.42, 0.13)

−0.30 (−0.57, −0.02)

−0.15 (−0.48, 0.18)

0.382

CDR sum of boxes,n= 1080

 12 months

0.12 (0.07, 0.16)

0.24 (0.15, 0.34)

0.13 (0.03, 0.23)

0.014

 24 months

0.13 (0.07, 0.18)

0.32 (0.20, 0.43)

0.19 (0.06, 0.32)

0.004

 36 months

0.23 (0.16, 0.30)

0.36 (0.22, 0.51)

0.14 (−0.03, 0.30)

0.098

 48 months

0.34 (0.26, 0.41)

0.52 (0.35, 0.69)

0.18 (−0.01, 0.38)

0.061

Executive function composite scoree,n= 1068

 12 months

−0.03 (−0.07, 0.004)

−0.07 (−0.18, 0.04)

−0.04 (−0.15, 0.08)

0.544

 24 months

−0.07 (−0.11, −0.03)

−0.11 (−0.23, 0.004)

−0.05 (−0.17, 0.07)

0.452

 36 months

−0.12 (−0.17, −0.07)

−0.18 (−0.30, −0.05)

−0.06 (−0.19, 0.07)

0.381

 48 months

−0.15 (−0.19, −0.10)

−0.21 (−0.34, −0.08)

−0.06 (−0.20, 0.08)

0.379

Attention scoref,n= 1080

 12 months

−0.03 (−0.07, 0.004)

−0.07 (−0.18, 0.04)

−0.04 (−0.15, 0.08)

0.544

 24 months

−0.07 (−0.11, −0.03)

−0.11 (−0.23, 0.004)

−0.05 (−0.17, 0.07)

0.452

 36 months

−0.12 (−0.17, −0.07)

−0.18 (−0.30, −0.05)

−0.06 (−0.19, 0.07)

0.381

 48 months

−0.15 (−0.19, −0.10)

−0.21 (−0.34, −0.08)

−0.06 (−0.20, 0.08)

0.379

  1. Significant associations in bold. Models were adjusted by sex, age, BMI, MAPT group, CDR status at baseline, GDS score, and ApoE ε4 genotype
  2. Abbreviations: MCP-1 Monocyte Chemoattractant Protein-1, MMSE Mini-Mental State Examination, CDR Clinical Dementia Rating
  3. aHigh MCP-1 defined as values in the 4th quartile (> 251 pg/mL)
  4. bNegative values for within-group differences mean cognitive decline, except for CDR sum of boxes (for which it is given by positive value)
  5. cNegative values for between-group differences indicate more pronounced cognitive decline among the high-plasma MCP-1 group, except for CDR sum of boxes (for which it is given by positive values)
  6. dBased on the mean z-score of 4 cognitive tests (free and total recall of the Free and Cued Selective Reminding test, 10 MMSE orientation items, Digit Symbol Substitution Test, and Category Naming Test)
  7. eBased on the mean z-score of 3 executive function tests (Controlled Oral Word Association Test, the Category Naming Test and the Trail Making Test-Part B)
  8. fBased on the mean z-score of 2 attention tests (Digit Symbol Test and the Trail Making Test-Part A)